ClinicalTrials.gg
Not yet recruitingNCT06606483Updated Sep 24, 2024

A Study to Evaluate the Efficacy and Safety of MDR-001 in Subjects Who Are Obesity or Overweight

A Phase 2 interventional study of MDR-001 and Placebo in Obesity and Overweight and Obesity, sponsored by MindRank AI Ltd. Not yet recruiting at 19 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-09-24.

Sponsored by MindRank AI Ltd · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 3 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 600 studies in Obesity with a site in China — 221 open to participants now, 282 under way, 67 of them phase 3. Obesity · China.

Planned enrollment
123rd of 502
300 · median 120
Started
2024
with 76 others
Phase 2
52 of 600
17 open now
Primary completion
2025-07
later than 33 of 280 live
Registered
301st of 600
by date

Among the 600 studies in Obesity with a site in China, this one is the 123rd largest by planned enrollment of the 502 interventional ones that give a count, is one of 77 that started in 2024, is one of 52 in phase 2, reaches primary completion later than 33 of the 280 other live ones, and was the 301st registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

221 of the 600 studies in Obesity with a site in China are open now. Recruiting first, the newest first:

216 more — sign in →

All 221 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 600 studies in Obesity with a site in China, or all of them as a file.
02

Study summary

This is a 24 weeks, multicenter, randomized, double-blind, placebo, parallel-controlled Phase IIb trail comparing the efficacy and safety of MDR-001 tablet versus placebo as an adjunct to a reduced calorie diet and increased physical activity in subjects with overweight or obesity, and to explore the optimal dose selection to support the subsequent Pivotal trial.

03

Conditions studied

  • Obesity
  • Overweight and Obesity
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. In accordance with adequate , the subject voluntarily signs the Informed Consent Form (ICF).
  2. Male or female participants aged ≥18 and ≤ 65 years, who have signed the Informed Consent Form (ICF)
  3. Have of

    • obesity: ≥28 kg/m2
    • overweight: ≥24 kg/m2 and ≤28 kg/m2 with at least 1 of the following weight-related comorbidities

      1. prediabetes: 6.1 mmol/L (110 mg/dL) ≤FPG≤7.0 mmol/L (126 mg/dL) ; and/or 5.7%≤≤6.5% 2)Hypertension: medical record for Hypertension, or diagnosis of hypertension for the first time during screening (with at least three measurements spaced across at least over a period of two days, defining hypertension as a systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg).
      1. Dyslipidemia: medical record for dyslipidemia (regardless of medication treatment) or TC≥5.2 mmol/L (200 mg/dl), and/or LDL-C≥3.4 mmol/L (130 mg/dl), and/or HDL-C\<1.0 mmol/L (40 mg/d l), and/or TG≥1.7 mmol/L (150 mg/dl) at screening 4) fatty liver disease(FLD): Presence of FLD confirmed by imaging studies within three months prior to screening, or diagnosis of FLD at screening 5) obstructive sleep apnea 6) Presence of weight-bearing joint pain during the screening period or within three months prior to screening. (Acceptance of patient self-description)
  4. The weight change achieved through dietary and exercise control should not exceed a 5% variation within three months prior to screening. (Acceptance of patient self-description)
  5. Potential participants with fertility potential (including the partners of male participants) must not have any plans for conception or sperm donation from the screening period until 6 months after the last dose administration, and they should be willing to use at least one effective method.
  6. The participant must have a thorough understanding of the trial objectives, be able to communicate effectively with the investigators, and be capable of comprehending and adhering to all the requirements of this trial, including following the medication regimen and lifestyle guidance as outlined in the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Have obesity induced by other disorders or drugs, including elevated cortisol hormones (such as Cushing's syndrome), polycystic ovary syndrome, obesity due to pituitary and hypothalamic injuries, etc
  2. Previous diagnosis of diabetes mellitus (including Type 1 diabetes, Type 2 diabetes, diabetes caused by pancreatic injury, or other types of diabetes) or diagnosis of Type 2 diabetes at the time of screening/randomization, defined as: ≥ 6.5%; and/or fasting plasma glucose ≥ 7.0 mmol/L (126 mg/dL); and/or random plasma glucose ≥ 11.1 mmol/L (200 mg/dL).
  3. A history of at least one episode of hypoglycemia occurring within the 3 months prior to screening, without apparent precipitating causes, is defined as FPG \<2.8 mmol/L (50 mg/dL) and/or the presence of marked symptoms of hypoglycemia.
  4. A history of psychiatric disorders, addictive diseases, or other conditions that may impair the ability of the participant to provide .
  5. A history of suicidal ideation or suicidal behavior.
  6. Have any of the following major cardiovascular and cerebrovascular conditions within 6 months prior to Screening 1) myocardial infarction(MI), percutaneous coronary intervention(PCI), coronary artery bypass grafting(CABG), heart valve repair/replacement, unstable angina, hemorrhagic stroke (stroke), ischemic stroke (including (TIA)); 2) Functional Classification III or IV congestive heart failure
  7. A history of gout within the past six months prior to screening.
  8. A history of proliferative retinopathy or macular degeneration.
  9. Have a history of less than 5 years or diagnosis of malignancy at screening (other than cured basal cell skin cancer, or in situ carcinomas of the cervix)
  10. Have a known self or family history (first-degree relative) of medullary thyroid carcinoma or multiple endocrine neoplasia type 2
  11. Have a personal or family history of long syndrome, family history of sudden death in a first-degree relative (parents, siblings, or children) before the age of 40 years, and/or a personal history of unexplained syncope within the last year.
  12. During the screening phase, subjects exhibited thyroid function abnormalities uncontrolled (TSH>6 mIU/L or \<0.4 mIU/L) by a stable medication regimen (stable dosages for three months or more), Subclinical hypothyroidism requiring no treatment (with TSH levels \<10.0 mIU/L and normal range of FT3 and FT4) is excluded.
  13. Within the six months preceding screening, subjects experienced severe gastrointestinal disorders (such as active gastric ulcers), or underwent gastrointestinal surgery (Appendectomy, cholecystectomy, or other gastrointestinal endoscopic surgeries deemed by the investigator to have no significant impact on gastrointestinal motility are excluded), or have a known gastric emptying abnormality (for example, pyloric obstruction, gastroparesis)
  14. Amylase/lipase>3 at screening or have had a history of chronic or acute pancreatitis
  15. Have had a history of chronic or acute hepatitis; or have signs and symptoms of any other liver disease other than nonalcoholic fatty liver disease at screening, or any of the following, as determined by the laboratory during screening 1) or AST ≥3×ULN 2)≥1.5×ULN 3)ALP≥3×ULN
  16. Subjects with a history of acute biliary tract disease (cholecystitis, gallstones, or bile duct stones) within one year prior to screening, or suffer from biliary tract disease accompanied by related clinical symptoms which should be treated at screening/randomization, are deemed unsuitable for participation in this clinical trial by the investigator.
  17. The subjects exhibit or a suspected hypersensitivity to GLP-1 receptor agonists (GLP-1RAs) or to .
  18. Have a history of drug or alcohol abuse
  19. Have a history of alcoholism within the prior 3 months of study screening (750 mL of beer or 250 mL of wine or 50 g of distilled spirits per day)
  20. Have taken within 3 months prior to screening medications or food intended to affect body weight, including but not limited to:
  1. Approved/unapproved weight-loss drugs: Orlistat, Sibutramine Hydrochloride, Phentermine Resin Complex, Phentermine-Topiramate, Contrave, Semaglutide, Liraglutide, Phendimetrazine, Methamphetamine, etc.; 2) GLP-1RA or GLP-1R/GCGR or GIPR/GLP-1R or GIPR/GLP-1R/GCGR or DPP-4 inhibitors 3) Hypoglycemic drugs, such as metformin, sodium-glucose cotransporter 2 (SGLT2) inhibitors, thiazolidinediones (TZDs), etc.
  1. Systemic (including intravenous, oral, intra-articular administration) 5) Tricyclic antidepressants or other antipsychotic or antiepileptic drugs intended to affect body weight (such as: Mirtazapine, Paroxetine, Clozapine, Olanzapine, Risperidone, Paliperidone, Valproic acid, Valproic acid derivatives, lithium salt).
  1. Have a prior or planned surgical treatment for obesity (excluding acupuncture, cupping, thread lift, liposuction or abdominoplasty, if performed 1 year prior to screening) or planned surgical treatment or acupuncture, cupping, thread lift, liposuction or abdominoplasty during clinical trial 22. Screening within 3 months before the large or medium-sized surgery or serious trauma, severe infection occurred, the investigator judged not suitable for this trial or during the trial period is planned to receive surgery (Outpatient surgeries that are judged by the investigator to have no impact on the safety of the subjects and the results of the trial are excluded) 23. Have had a history of organ transplantation 24. The use of any drugs or foods known to potently or moderately inhibit and/or P-gp is prohibited within 28 days prior to the first administration of the study drug and throughout the duration of the trial.
  1. Have poorly controlled hypertension (mean seated systolic BP ≥160 mm Hg or mean seated diastolic BP ≥100 mm Hg) at screening (Pre-randomization review; seated, at rest for at least 5 minutes, with a second measurement taken to average the values if the difference between the two measurements exceeds ≥5 mmHg, with a third measurement taken if necessary, with at least a one-minute interval between each test. The final test result is the arithmetic mean of the three test results) 26. positive or antibodies or antibodies or syphilis antibodies at screening 27. During the screening phase, laboratory examination results meet any of the following criteria:
  1. calcitonin≥50 ng/L
  2. estimated ≤60 mL/min/1.73 m2, calculated by CKD-EPI
  3. uncontrolled severe dyslipidemia, with triglyceride (TG) levels ≥ 5.65 mmol/L (500 mg/dL) treated by conventional lipid-lowering medications.
  4. >1.5×ULN
  5. value \<110 g/L (females) or \<120 g/L (males) 28. Screening for QTcF>450 ms (males) and QTcF>470 ms (females) at rest (at least 5 min, repeat measurement once to obtain the average, with a 2 min ± 60 s interval between the two measurements).
  1. Participating in another clinical trial; or, if on treatment with the drug or device, the time since the last dose or cessation of treatment is ≤3 months or 5 half-lives (t1/2) of the investigational drug (whichever is longer) prior to the first day of this trial screening.
  1. Have a blood transfusion or severe blood loss ≥500 mL within the prior 3 months of study screening or received blood transfusion before screening 31. Pregnant or lactating females; 32. Parties directly associated with this trial, including but not limited to, the principal investigator(s), staff members of the trial centers, and/or their immediate family members. Immediate family members are defined as spouses, parents, children, or siblings, whether born or legally adopted.
  1. Inability to complete the trial for reasons unrelated to the study, or any other condition or prior therapy that would make the participant unsuitable for this study (such as participant refusal to adhere to the prescribed weight-loss medication exclusively during the trial period).
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    90 mg MDR-001

    Drug: MDR-001 Administered orally

    Drug: MDR-001

  • Experimental
    120 mg MDR-001

    Drug: MDR-001 Administered orally

    Drug: MDR-001

  • Experimental
    150 mg MDR-001

    Drug: MDR-001 Administered orally

    Drug: MDR-001

  • Experimental
    180 mg MDR-001

    Drug: MDR-001 Administered orally

    Drug: MDR-001

  • Placebo comparator
    placebo

    Drug: MDR-001 Administered orally

    Drug: Placebo

Interventions

  • Oral administration of small molecule MDR-001 tablets

  • DrugPlacebo

    Administered orally placebo

06

What researchers measure

Primary outcomes

  1. Percent Change in Body Weight From Baseline at Week 24

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Change in Body Weight (kg) from Baseline at Week 24

    Time frame: Baseline, Week 24

  2. Percentage of Study Participants Who Achieve ≥5% Body Weight Reduction at Week 24

    Time frame: Baseline, Week 24

  3. Percentage of Study Participants Who Achieve ≥10% Body Weight Reduction at Week 24

    Time frame: Baseline, Week 24

  4. Change in BMI (kg/m2) from Baseline at Week 24

    Time frame: Baseline, Week 24

  5. Change in Waist Circumference from Baseline at Week 24

    Time frame: Baseline, Week 24

  6. Change in hyperlipidemia (TC, TG, LDL-C, HDL-C, nHDL-C) From Baseline at Week 24

    Time frame: Baseline, Week 24

  7. Change in Blood Pressure (SBP, DBP) from Baseline at Week 24

    Time frame: Baseline, Week 24

  8. Change in Blood Glucose (HbA1c, FPG) from baseline at Week 24

    Time frame: Baseline, Week 24

Other outcomes

  1. To assess safety and tolerability of study interventions

    Time frame: up to 25 weeks

  2. The time-course variation of MDR-001 plasma concentration

    Time frame: up to 25 weeks

  3. MDR-001 Population Pharmacokinetic (PopPK) Analysis

    Time frame: up to 25 weeks

  4. Percentage of Study Participants Who Achieve ≥15% Body Weight Reduction at Week 24

    Time frame: Baseline, Week 24

07

Study locations

19 sites
  • The Second Hospital Of Anhui Medical University
    Hefei, Anhui, China
    • Tianrong Pan · Principal investigator
  • The People's Hospital of Suancheng City
    Xuancheng, Anhui, China
    • Chongbing Huang · Principal investigator
  • Zibo Central Hospital
    Zibo, Anhui, China
    • Xiaodong Zhao · Principal investigator
  • Peking University People's Hospital
    Beijing, Beijing, China
    • Linong Ji · Principal investigator
  • The Third People's Hospital of Hainan
    Haikou, Hainan, China
    • Ling Lin · Principal investigator
  • The Second Hospital Of Hebe Medical University
    Shijiazhuang, Hebei, China
  • The Fourth Affiliated Hospital of Harbin Medical University
    Harbin, Heilongjiang, China
    • Zhifeng Cheng · Principal investigator
  • The first Affiliated Hospital of Henan University of Science and Technology
    Luoyang, Henan, China
    • Yujin Ma · Principal investigator
  • The First Affiliated Hospital of Nanyang Medical College
    Nanyang, Henan, China
    • Dexue Liu · Principal investigator
  • The First People's Hospital of Chenzhou City
    Chenzhou, Hunan, China
    • Weihong Song · Principal investigator
  • Zhuzhou Central Hospital
    Zhuzhou, Hunan, China
    • Lihua Zhou · Principal investigator
  • Second Hospital of Jilin University
    Changchun, Jilin, China
    • Hanqing Cai · Principal investigator
  • Daqing People's Hospital
    Daqing, Jilin, China
    • Yang Liu · Principal investigator
  • Panjin Liaoyou Gem Flower Hospital
    Panjin, Liaoning, China
    • Xin Zhang · Principal investigator
  • The Fifth People's Hospital of Shenyang
    Shenyang, Liaoning, China
    • Yuzhu Zhao · Principal investigator
  • Central hospital of Jinan
    Jinan, Shandong, China
    • Xiaolin Dong · Principal investigator
  • Shanxi Bethune Hospital
    Taiyuan, Shanxi, China
    • Shiwei Liu · Principal investigator
  • Xianyan Hospital of Yanan Univisity
    Xianyang, Shanxi, China
    • Fang Wang · Principal investigator
  • Yichang Central People's Hospital
    Yichang, Sichuan, China
    • Jun Zeng · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2024; primary completion for Jul 2025, 10 months later.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's planned 10 months is below that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2024
First posted
Sep 23, 2024
StartEst.
Sep 23, 2024
Primary completionEst.
Jul 30, 2025
CompletionEst.
Sep 30, 2025
Last update
Sep 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06606483
Lead sponsor
MindRank AI Ltd
Responsible party
Sponsor
First posted
Sep 23, 2024
Start date
Sep 23, 2024 (estimated)
Primary completion
Jul 30, 2025 (estimated)
Completion
Sep 30, 2025 (estimated)
Last update
Sep 24, 2024

Study contacts

Ruowen Guo
Contact
ruowen.guo@mindrank.cn
+86 0571-85233836

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MDR-001

Start the discussion